1. Home
  2. ARVN vs BOE Comparison

ARVN vs BOE Comparison

Compare ARVN & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.04

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Logo Blackrock Enhanced Global Dividend Trust of Beneficial Interest

BOE

Blackrock Enhanced Global Dividend Trust of Beneficial Interest

HOLD

Current Price

$11.78

Market Cap

649.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
BOE
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
649.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
BOE
Price
$8.04
$11.78
Analyst Decision
Buy
Analyst Count
19
0
Target Price
$15.05
N/A
AVG Volume (30 Days)
680.3K
102.6K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
7.30%
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$10.59
52 Week High
$14.22
$12.18

Technical Indicators

Market Signals
Indicator
ARVN
BOE
Relative Strength Index (RSI) 46.65 47.27
Support Level $7.35 $11.75
Resistance Level $10.18 $11.79
Average True Range (ATR) 0.41 0.18
MACD 0.17 -0.02
Stochastic Oscillator 70.20 42.39

Price Performance

Historical Comparison
ARVN
BOE

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest

Blackrock Enhanced Global Dividend Trust is a closed-end management investment company. Its investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in equity securities issued by companies located in countries throughout the world.

Share on Social Networks: